Clinical trials: Esophagogastric Junction
Cervical Esophagus Adenocarcinoma, Clinical Stage II Esophageal Adenocarcinoma AJCC v8
NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer
The purpose of this Phase I study is to determine the recommended phase 2 dose (RP2D) and safety profile of NBTXR3 activated by radiation therapy with concurrent chemotherapy for the treatment of patients with esophageal…
- Conditions
- Cervical Esophagus Adenocarcinoma, Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8
- Trial name
- NCT04615013
- Testing
- Capecitabine, Carboplatin, Docetaxel
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- M.D. Anderson Cancer Center
Stomach Cancer, Gastro Esophageal Junction Cancer
Neoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Resectable Gastric and GE-junction Cancer (PANDA)
In this explorative study, patients with resectabel cancer of the stomach or stomach-oesophagealjunction cancer will receive neoadjuvant treatment.
- Trial name
- PANDA (NCT03448835)
- Testing
- Atezolizumab, Capecitabine, Oxaliplatin
- Where
- 2 sites in Netherlands
- Volunteers
- 20 people
- Sponsor
- The Netherlands Cancer Institute
Gastric Carcinoma, Gastroesophageal Junction Carcinoma
Celecoxib/Oxaliplatin/Capecitabine for Gastric/Gastroesophageal Junction Carcinoma
Gastric cancer is the second most common neoplasm in the world. Early diagnosis and surgical resection improve the survival and the chance of cure.
- Trial name
- NCT00256321
- Testing
- Oxaliplatin, Capecitabine, Celecoxib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of California, Irvine
Gastric Cancer (GC), Siewert Type III Adenocarcinoma of Esophagogastric Junction
Immediate and Functional Results of Different Types of Reconstructions After Proximal Gastrectomy For Gastric and Esophagogastric Junction Cancer
Proximal gastric and esophagogastric junction cancers comprise up to 40% of gastric malignancies. For localized disease, proximal gastrectomy is the main radical procedure, but reconstruction of GI tract often leads to…
- Conditions
- Gastric Cancer (GC), Siewert Type III Adenocarcinoma of Esophagogastric Junction, Siewert Type II Adenocarcinoma of Esophagogastric Junction
- Trial name
- PROXISTAT (NCT07441785)
- Testing
- Proximal Gastrectomy
- Where
- Russia
- Volunteers
- 400 people
- Sponsor
- P. Herzen Moscow Oncology Research Institute
Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Neoadjuvant Therapy
Neoadjuvant Cadonilimab Combined With Perioperative Oxaliplatin Plus S1 for Diffuse or Mixed Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
This study aims to investigate the efficacy and safety of neoadjuvant cadonilimab in combination with perioperative SOX chemotherapy, compared to perioperative SOX chemotherapy alone, in patients with diffuse or mixed-type…
- Conditions
- Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Neoadjuvant Therapy, Adjuvant Chemotherapy, pCR Rate
- Trial name
- NCT06949033
- Testing
- Neoadjuvant cadonilimab combined with perioperative SOX
- Where
- 4 sites in China
- Volunteers
- 668 people
- Sponsor
- Zuoyi Jiao
Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
This study is open to adults aged 18 years and older with different types of HER2+ cancer that has spread and cannot be removed by surgery.
- Conditions
- Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
- Trial name
- NCT06324357
- Testing
- Zongertinib, Trastuzumab deruxtecan, Trastuzumab emtansine
- Where
- 104 sites in United States, Belgium and 8 more
- Volunteers
- 910 people
- Sponsor
- Boehringer Ingelheim
Esophageal Neoplasms, Adenocarcinoma of the Gastroesophageal Junction
A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab
A study to evaluate the safety and tolerability of DKN-01 in combination with weekly paclitaxel or pembrolizumab in participants with relapsed or refractory Esophagogastric Malignancies
- Conditions
- Esophageal Neoplasms, Adenocarcinoma of the Gastroesophageal Junction, Gastroesophageal Cancer, Squamous Cell Carcinoma
- Trial name
- P102 (NCT02013154)
- Testing
- DKN-01 150 mg, Paclitaxel, Pembrolizumab
- Where
- 10 sites in United States
- Volunteers
- 151 people
- Sponsor
- Leap Therapeutics, Inc.
Gastric Cancer, Gastroesophageal Junction Cancer
MRI and CT in Gastroesophageal Junction or Upper Gastric Adenocarcinoma
Accurate preoperative Siewert classification, precise assessment of the extent of esophageal involvement, and staging is crucial for determining the appropriate surgical approach and achieving negative resection margins.
- Trial name
- NCT06640153
- Testing
- mpMRI
- Where
- China
- Volunteers
- 100 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Adebrelimab (SHR-1316), XELOX
A Phase II Trial of Perioperative Adebrelimab Combined With XELOX in Resectable Locally Advanced Gastric/Gastroesophageal Junction Cancer (GC/GEJC)
To observe and evaluate the efficacy and safety of adebrelimab combination chemotherapy regimen in the perioperative treatment of surgically resectable gastric cancer/adenocarcinoma of the gastroesophageal junction.
- Conditions
- Adebrelimab (SHR-1316), XELOX, GC/GEJC
- Trial name
- NCT06506292
- Testing
- Adebrelimab, XELOX
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Stomach Neoplasms, Esophagogastric Junction Disorder
Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer
NeoRacing is a randomized phase II trial carried out at Fudan University Shanghai Cancer Center (FUSCC) in China. The study can be divided into the screening stage, treatment stage and follow-up stage.
- Conditions
- Stomach Neoplasms, Esophagogastric Junction Disorder, Neoadjuvant Therapy, Chemoradiotherapy
- Trial name
- NeoRacing (NCT05161572)
- Testing
- Oxaliplatin, Tegafur-Gimeracil-Oteracil, Sintilimab
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Fudan University
Gastric Cancer, Apatinib
Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer
The study is to investigate the efficacy and safety of apatinib for the first-fine treatment in elderly patients with locally advanced or metastatic adenocarcinoma of stomach or gastroesophageal junction, unable or unwilling to…
- Conditions
- Gastric Cancer, Apatinib, Biomarker
- Trial name
- NCT03219593
- Testing
- Apatinib mesylate tablets
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The First Affiliated Hospital of Bengbu Medical University
Stage IV Esophageal Adenocarcinoma, Stage IV Esophageal Squamous Cell Carcinoma
Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers
This phase II trial studies how well radiation therapy works for the treatment of gastrointestinal cancer that are spreading to other places in the body (metastatic).
- Conditions
- Stage IV Esophageal Adenocarcinoma, Stage IV Esophageal Squamous Cell Carcinoma, Stage IV Gastric Cancer, Stage IV Adenocarcinoma of the Gastroesophageal Junction
- Trial name
- NCT04221893
- Testing
- Radiation Therapy (RT)
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- University of California, San Francisco
HER2-positive Advanced Gastric Cancer, HER2-positive Gastroesophageal Junction Adenocarcinoma
A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)
Trastuzumab deruxtecan (T-DXD) as monotherapy is indicated for the treatment of adult patients with advanced HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior…
- Trial name
- NCT05993234
- Testing
- Trastuzumab deruxtecan
- Where
- 39 sites in Austria, Belgium and 2 more
- Volunteers
- 257 people
- Sponsor
- Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Metastatic HER2+ Advanced Breast Cancer, Breast Neoplasms
Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)
The primary purpose of this study is to characterize the safety and tolerability of tucatinib (MK-7119) in Chinese participants with human epidermal growth factor receptor 2 positive (HER2+) advanced breast cancer, gastric or…
- Conditions
- Metastatic HER2+ Advanced Breast Cancer, Breast Neoplasms, Gastric or Gastroesophageal Junction Adenocarcinoma (GEC), Colorectal Cancer
- Trial name
- NCT05382364
- Testing
- Tucatinib
- Where
- 5 sites in China
- Volunteers
- 25 people
- Sponsor
- Pfizer
Gastric Carcinoma
A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
The purpose of this study is to evaluate the efficacy and safety of Disitamab Vedotin combined with Trastuzumab and Tislelizumab Versus Chemotherapy Combined with Trastuzumab with or without Pembrolizumab as First-Line Treatment…
- Trial name
- NCT07315750
- Testing
- Disitamab Vedotin, Tislelizumab, CAPOX (oxaliplatin/capecitabine)
- Where
- China
- Volunteers
- 555 people
- Sponsor
- RemeGen Co., Ltd.
Gastric Cancer
A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)
This study is to compare and evaluate the efficacy and safety of ONO-4538 in combination with ipilimumab and chemotherapy versus chemotherapy in chemotherapy-naïve participants with HER2-negative unresectable advanced or…
- Trial name
- NCT05144854
- Testing
- ONO-4538, Ipilimumab, Oxaliplatin
- Where
- 57 sites in Japan, South Korea and 1 more
- Volunteers
- 626 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Gastric Cancer, Gastroesophageal Junction Cancer
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension
The purpose of this study is to evaluate the efficacy of pembrolizumab (MK-3745) in the neoadjuvant (prior to surgery) or adjuvant (after surgery) treatment of previously untreated Chinese adults with gastric and gastroesophageal…
- Trial name
- NCT04882241
- Testing
- Pembrolizumab, Cisplatin, Capecitabine
- Where
- 20 sites in China
- Volunteers
- 120 people
- Sponsor
- Merck Sharp & Dohme LLC
HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer
This is an open,multicentre phase Ib/II study. The purpose of phase Ib is to evaluated the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of SHR-A1811 in combination with chemotherapy…
- Trial name
- NCT05671822
- Testing
- SHR-A1811 and SHR-1701, SHR-A1811 and capecitabine, SHR-A181, SHR-1701, and capecitabine
- Where
- China
- Volunteers
- 258 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Carcinoma, Non-Small Cell Lung, HER2 Negative Breast Neoplasms
A Study of SGN-STNV in Advanced Solid Tumors
This trial will look at a drug called SGN-STNV to find out whether it is safe for patients with solid tumors. It will study SGN-STNV to find out what its side effects are.
- Conditions
- Carcinoma, Non-Small Cell Lung, HER2 Negative Breast Neoplasms, Ovarian Neoplasms, Uterine Cervical Neoplasms
- Trial name
- NCT04665921
- Testing
- SGN-STNV
- Where
- 18 sites in United States, Canada and 4 more
- Volunteers
- 111 people
- Sponsor
- Seagen Inc.
Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Study of T-DXd Monotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma Who Have Received 2 or More Prior Regimens
This is a Phase II, open-label, single-arm, multicentre, study in China assessing the efficacy and safety of T-DXd in participants with HER2-expressing advanced gastric or GEJ adenocarcinoma who have received at least 2 prior…
- Trial name
- DG-06 (NCT04989816)
- Testing
- Trastuzumab Deruxtecan
- Where
- 24 sites in China
- Volunteers
- 95 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.